-
Media Release
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
-
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
-
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
-
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
-
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media Release
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients